Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Read why I think DNA ...

There’s plenty of empty lab space around Greater Boston these days, and a lot of competition for life-science tenants. Now ...

Ginkgo Bioworks falls short on Q4 revenue and projects weak 2025 guidance. Learn about DNA stock's valuation risks, cash ...

Ginkgo already canceled its plans to move into Biofab1, a new 260,000-square-foot lab data center it's been building near its ...

Pre-earnings options volume in Ginkgo Bioworks (DNA) is normal with calls leading puts 8:5. Implied volatility suggests the market is ...

Cell Engineering revenue $110M-$130M with potential upside from the recent launch of Tools offerings Ginkgo expects Biosecurity ...

A police chief has torn up a diversity guide that told officers to avoid saying 'blacklisted' and 'black sheep' in case it offended anyone. Hertfordshire's Police and Crime Commissioner ...

Ginkgo biloba benefits have been claimed for centuries, with health treatments meant to help improve cognitive function and treat asthma, COPD, and bladder disorders. Studies suggest that it acts on ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.32 in the latest trading session, marking a -0.48% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.27%.

Ginkgo Bioworks Holdings, Inc. (DNA) shares ended the last trading session 14.5% higher at $16.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...